Immune checkpoint inhibitors (ICIs), a major type of cancer immunotherapy, don't do much for hospitalized cancer patients, ...

"Without careful consideration of the impact of these changes, we risk long-term damage" to medical research, writes Dr. George Weiner.

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

KAIST researchers have discovered a molecular switch that can revert cancer cells back to normal by capturing the critical ...

Blood clots form in response to signals from the lungs of cancer patients -- not from other organ sites, as previously thought -- according to a preclinical study. Clots are the second-leading cause ...

A device developed by the Institute of Bioengineering of Catalonia and the Research Institute of Hospital del Mar allows replicating tumors and their environment to analyze the response to therapies.

Oncologist Dr. Sarah Cate told Newsweek: "Many women simply don't make time for themselves, since they are working and often ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...